CERS Cerus Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CERS

Price (delayed)

$2.6

Market cap

$523.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.03

Enterprise value

$582.16M

?
Relative Growth: Rel. Growth: 64
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 45

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies ...

Highlights
CERS's EPS has surged by 70% year-on-year and by 40% since the previous quarter
The company's net income has surged by 64% YoY and by 29% QoQ
The quick ratio has declined by 22% year-on-year
The gross margin has declined by 6% year-on-year and by 2.1% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.cerus.com
Peers: HAE BSX MLSS

Key stats

What are the main financial stats of CERS

CERS stock price

How has the Cerus stock price performed over time
Intraday
-2.62%
1 week
2.77%
1 month
-7.47%
1 year
62.5%
YTD
26.21%
QTD
-10.96%

Financial performance

How have Cerus's revenue and profit performed over time
Revenue
$248.01M
Gross profit
$141.78M
Operating income
-$1.62M
Net income
-$6.78M
Gross margin
57.2%
Net margin
-2.7%
Cerus's operating margin has surged by 87% YoY and by 46% QoQ
CERS's operating income has surged by 86% year-on-year and by 49% since the previous quarter
Cerus's net margin has surged by 69% YoY and by 31% QoQ
The company's net income has surged by 64% YoY and by 29% QoQ

Price vs fundamentals

How does CERS's price correlate with its fundamentals

Growth

What is Cerus's growth rate over time

Valuation

What is Cerus stock price valuation
P/E
N/A
P/B
7.44
P/S
2.1
EV/EBIT
456.24
EV/EBITDA
105.54
EV/Sales
2.35
CERS's EPS has surged by 70% year-on-year and by 40% since the previous quarter
CERS's equity is up by 26% year-on-year and by 3.7% since the previous quarter
CERS's price to book (P/B) is 23% higher than its last 4 quarters average of 6.2 but 4.5% lower than its 5-year quarterly average of 8.0
The stock's price to sales (P/S) is 27% more than its last 4 quarters average of 1.7 but 23% less than its 5-year quarterly average of 2.8
CERS's revenue is up by 15% year-on-year

Efficiency

How efficient is Cerus business performance
The ROIC has soared by 115% YoY
CERS's return on sales has surged by 111% year-on-year
CERS's return on equity has surged by 70% year-on-year and by 33% since the previous quarter
Cerus's return on assets has surged by 67% YoY and by 30% QoQ

Dividends

What is CERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CERS.

Financial health

How did Cerus financials performed over time
CERS's total assets is 53% greater than its total liabilities
The quick ratio has declined by 22% year-on-year
Cerus's total liabilities has decreased by 14% YoY and by 13% QoQ
Cerus's debt is 10% higher than its equity
Cerus's debt to equity has decreased by 38% YoY and by 24% QoQ
CERS's equity is up by 26% year-on-year and by 3.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.